GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced US government contracts totalling approximately $1 billion (USD) to purchase sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, which the US Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) in May 2021.
GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment
November 19, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022